Subvisible Particulate Matter in Therapeutic Protein Injections


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Strategies for determining particulate matter in therapeutic protein injections, including extrinsic and intrinsic particles, are reviewed. Special attention is devoted to the advantages and limitations of various methods used for these purposes, each of which enables different particle characteristics to be determined. The source of particles (extrinsic, intrinsic, or inherent) can be understood better and particle-size distribution and other characteristics can be studied and used to differentiate them if methods based on different measurement principles are used. Protein aggregates in drugs have broad particle-size distributions, from oligomers to particles reaching hundreds of microns. The particle properties can be used to assess the risk associated with protein aggregates in the drug and to study their possible formation mechanisms. Such information could be useful during drug development and manufacturing to reduce the particulate matter content.

作者简介

E. Novik

Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

编辑信件的主要联系方式.
Email: Novik@expmed.ru
俄罗斯联邦, 8/2 Petrovskii Blvd., Moscow, 127051

A. Dorenskaya

Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: Novik@expmed.ru
俄罗斯联邦, 8/2 Petrovskii Blvd., Moscow, 127051

N. Borisova

Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: Novik@expmed.ru
俄罗斯联邦, 8/2 Petrovskii Blvd., Moscow, 127051

O. Gunar

Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: Novik@expmed.ru
俄罗斯联邦, 8/2 Petrovskii Blvd., Moscow, 127051

补充文件

附件文件
动作
1. JATS XML

版权所有 © Springer Science+Business Media, LLC, part of Springer Nature, 2019